tbuckley/cabot-search huggingface dataset:
Abstracts From the 34th American College of Nuclear Physicians Annual Meeting February 14–17, 2008 Newport Beach, CA
Journal: Clinical Nuclear Medicine (2009)

Log in or Register Subscribe to journalSubscribe Get new issue alertsGet alerts Enter your Email address: Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. Subscribe to eTOC Secondary Logo Journal Logo All Articles Images Videos Podcasts Blogs Advanced Search Toggle navigation Subscribe Register Login Articles & Issues Current IssuePrevious IssuesPublished Online First Collections ACNM MeetingsCMECommunication in OrganizationCOVID-19Feedback and RewardsFrom the American College of Nuclear MedicineHighly Cited and Frequently Read ArticlesPlanning and Conducting Meetings EffectivelyQuality and Safety in Health CareRecruitment of New PhysiciansTips for Giving a Memorable PresentationTips for LeadersTips for Physicians in Getting the Right Job ACNM ArticlesACNM Website For Authors Submit a ManuscriptInformation for AuthorsLanguage Editing ServicesAuthor Permissions Journal Info About the JournalEditorial BoardAdvertisingOpen AccessSubscription ServicesReprintsRights and Permissions All Articles Images Videos Podcasts Blogs Advanced Search
Y2K: The Moment of Truth
Authors: Ron Chepesiuk
Journal: Environmental Health Perspectives (1999)

It remains to be seen whether the world will move in time to fix the Y2K bug, or whether computers around the world will shut down when the clock strikes midnight on 31 December 1999. Y2K could have a serious impact on environmental facilities, particularly given the extent to which computer software and microchips are now involved in pollution control and environmental monitoring and protection systems.
Inflammation, Infection and Venous Thromboembolism
Authors: Meaghan E. Colling, Benjamin E. Tourdot, Yogendra Kanthi
Journal: Circulation Research (2021)

The association between inflammation, infection, and venous thrombosis has long been recognized; yet, only in the last decades have we begun to understand the mechanisms through which the immune and coagulation systems interact and reciprocally regulate one another. These interconnected networks mount an effective response to injury and pathogen invasion, but if unregulated can result in pathological thrombosis and organ damage. Neutrophils, monocytes, and platelets interact with each other and the endothelium in host defense and also play critical roles in the formation of venous thromboembolism. This knowledge has advanced our understanding of both human physiology and pathophysiology, as well as identified mechanisms of anticoagulant resistance and novel therapeutic targets for the prevention and treatment of thrombosis. In this review, we discuss the contributions of inflammation and infection to venous thromboembolism.
Magnetic navigation system for intracardiac pacing and mapping: Safety and equivalence study Mitchell N. Faddis, Andrew F. Hall, Michael Talcott, Jennifer Dehne, John C. Rauch, Jon C. Sell, Bruce D. Lindsay. Washington University School of Medicine, St. Louis, MO, Stereotaxis, Inc, St. Louis, MO
Journal: Journal of the American College of Cardiology (2001)
Cost-effectiveness of universal screening for germline BRCA mutations in metastatic pancreatic cancer.
Authors: Myles Ingram, Yoanna S Pumpalova, Jiheum Park, Francesca Lim, Jennifer S. Ferris, Susan Elaine Bates, Gulam Abbas Manji, Chung Yin Kong, Chin Hur
Journal: Journal of Clinical Oncology (2022)

536 Background: Germline BRCA1/2 mutations (gBRCAm) increase the risk of pancreatic ductal adenocarcinoma (PDAC). The NCCN 2020 guidelines recommend testing for gBRCAm in metastatic PDAC patients if the patients have a personal history and/or familial history of PDAC (current standard-of-care). However, given the advances made in genetic testing, universal gBRCAm testing for metastatic PDAC patients can be considered. The cost-effectiveness of universal gBRCAm screening has yet to be compared to the current standard-of-care. The purpose of our study was to explore the cost-effectiveness, treatment outcomes, costs, and quality-of-life impact of universal gBRCAm screening. Methods: We developed a decision-analytic mathematical model comparing the cost and health outcomes of universal gBRCAm screening against the current standard-of-care. Inputs for the model were estimated using clinical trial data and published literature. No intervention was used as a comparator. The primary endpoint was incremental cost-effectiveness ratios (ICERs) with a willingness-to-pay (WTP) threshold of $100,000 per quality-adjusted-life-year (QALY). Secondary endpoints included overall survival (OS), progression-free survival (PFS), life-years (LYs) and total cost of care (USD). Results: Universal gBRCAm screening was the cost-effective strategy, totaling incremental QALYs of 1.61 at a cost of $73,682 per QALY when compared to no intervention. A one-way sensitivity analysis found that the standard-of-care becomes the cost-effective strategy when the prevalence of gBRCAm is lowered to 2% of the base case. Conclusions: Our model found that universal gBRCAm screening is cost-effective and even cost-savings for patients with metastatic PDAC. Additional clinical trial data with sufficient follow-up are needed to confirm our findings.[Table: see text]
From the Food and Drug Administration
Authors: S. L. Nightingale
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mitochondrion-targeted supramolecular “nano-boat” simultaneously inhibiting dual energy metabolism for tumor selective and synergistic chemo-radiotherapy
Authors: Jie Gao, Zhilong Wang, Qingxiang Guo, Huan Tang, Zhongyan Wang, Cuihong Yang, Huirong Fan, Wenxue Zhang, Chunhua Ren, Jianfeng Liu
Journal: Theranostics (2022)

Rationale: Tumor energy metabolism has been a well-appreciated target of cancer therapy; however, the metabolism change of cancer cells between oxidative phosphorylation and glycolysis poses a challenge to the above.In this study, we constructed an innovative mitochondrion-targeted supramolecular "nano-boat" based on peptide self-assembly for tumor combined chemo-radiotherapy by simultaneously inhibiting the dual energy metabolism.Methods: A lipophilic self-assembled peptide and a positively charged cyclen were integrated to fabricate a brand new mitochondrion-targeted nano-platform for the first time.The indices of mitochondrial dysfunction including mitochondrial membrane potential, apoptosis proteins expression and ultrastructure change were evaluated using a JC-1 probe, western blotting and biological transmission electron microscopy, respectively.Energy metabolism assays were conducted on a Seahorse XF24 system by detecting the oxygen consumption rate and the glycolytic proton efflux rate.The radio-sensitization effect was investigated by colony formation, the comet assay, and γ-H2AX staining.Results: The supramolecular "nano-boat" could selectively kill cancer cells by much higher enrichment and reactive oxygen species generation than those in normal cells.In the cancer cells treated with the supramolecular "nano-boat", the dysfunctional morphological changes of the mitochondrial ultrastructure including swelling and pyknosis were evidently observed, and the endogenous mitochondrial apoptosis pathway was effectively triggered by abundant of cytochrome C leaking out.Concurrently, the dual metabolic pathways of glycolysis and oxidative phosphorylation were severely inhibited.More importantly, the supramolecular "nano-boat" displayed an excellent radio-sensitization effect with a sensitization enhancement ratio value as high as 2.58, and hence, in vivo efficiently combining radiotherapy yielded an enhanced chemo-radiotherapy effect.Conclusion: Our study demonstrated that the rationally designed peptide-based "nano-boat" could efficiently induce cancer cell apoptosis by the energy metabolism inhibition involving multiple pathways, which may provide the motivation for designing novel and universal mitochondria-targeted drug delivery systems for cancer therapy.
Relation of aortic valve and mitral anular calcification to cardiovascular mortality in American Indians: The strong heart study Javier Gonzalez, Richard B. Devereux, Vittorio Palmieri, Mary J. Roman, Jennifer E. Liu, Lyle Best, Elisa T. Lee, Richard R. Fabsitz, Barbara V. Howard. Weill Cornell Medical Center, New York, NY
Journal: Journal of the American College of Cardiology (2001)
From the Centers for Disease Control. Availability of primaquine phosphate
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab in Patients with Relapsed Follicular, Indolent, or Mantle Cell Lymphomas – 8-Year Follow-up Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)
Authors: Mathias J. Rummel, Christina Balser, Ulrich Kaiser, Hans Peter Böck, Martina Beate Stauch, Andrea Heider, Manfred Welslau, Christoph Losem, Eckhart Weidmann, Wolfgang Blau, Alexander Burchardt, Jürgen Barth, Frank Kauff, Axel Hinke, Wolfram Brugger
Journal: Blood (2014)
Tribute to Andrea Infuso
Authors: Collective Editorial team
Journal: Eurosurveillance (2006)

This special issue of Eurosurveillance is dedicated to the memory of Andrea Infuso, a dear and respected colleague and friend, who died suddenly on 20 September 2005 at the age of 44. Andrea was actively involved in the preparation of this special issue on vaccination and tuberculosis. As EuroTB coordinator since 2000, his knowledge of and contacts with all European experts involved in tuberculosis surveillance in Europe were very valuable in conceiving this thematic issue. The Euroroundup published in this issue, European survey of BCG vaccination policies and surveillance in children, 2005, written by Andrea as first author, is a posthumous publication.
Gynaecological cancer
Authors: K. E. Britton, M. Granowska
Journal: Clinical Nuclear Medicine (1998)

Cancers of the ovary, cervix and uterus are becoming increasingly common. Ovarian cancer is one of the most malignant tumours, and accounts for 6% of deaths from cancer in women in the Western world [1]. Whereas screening for cervical cancer has had some benefits and uterine cancer demonstrates itself usually with post-menopausal bleeding, ovarian cancer typically remains concealed until late in its course.
Implementation of Health Initiatives During a Cease-fire—Sudan, 1995
Journal: JAMA (1995)

In 1994, Sudan (1994 population: 27 million) reported to the World Health Organization (WHO) one third of the global total of cases of dracunculiasis (i.e., Guinea worm disease), which is targeted for eradication by the end of 1995 (1,2). On March 27, 1995, the government of Sudan announced a cease-fire of 2 months' duration in the 12-year-old civil war in the southern part of the country--both sides agreed to the cease-fire primarily to permit acceleration of efforts to eradicate dracunculiasis and to promote treatment of other health problems including onchocerciasis (i.e., liver blindness), administration of childhood vaccines, and distribution of vitamin A. This report summarizes the status of dracunculiasis and onchocerciasis in Sudan and provisional information on activities undertaken by the government of Sudan and other organizations during the cease-fire.
Baseline characteristics and results of percutaneous mechanical mitral commissurotomy in adolescents and young adults H�l�ne Eltchaninoff, Catherine Nafeh, Rapha�lle Carlot, Carlos Giron, Alain Cribier, for the Investigators of the Multicenter Registry. Charles Nicolle Hospital, Rouen, France
Journal: Journal of the American College of Cardiology (2001)
Superior mediastinal syndrome in a young child
Authors: K. S. Oh
Journal: JAMA (1969)

Dr. Adah M. Duncan: The patient, a 7-year-old white boy, had been treated for three weeks with antibiotics for what was thought to be upper-respiratory tract infection and had shown no response. During this period, he had become anorectic and had lost 2.7 kg (6 lb). During the week before admission, the patient was noted to turn blue and become acutely short of breath when he bent forward. On the day of admission, a stridor developed and he was severely short of breath at rest. At the time of admission, the respiratory rate was 32 per minute, temperature was 102 F (38.9 C), and blood pressure was 115/90 mm Hg. His face was pale and puffy with venous engorgement in the neck and over the chest. There was a firm, palpable supraclavicular lymph node on the left side measuring 1.5 cm in diameter. Breath sounds were decreased bilaterally, and there
Building a more resilient cancer healthcare system
Authors: None The Lancet Oncology
Journal: The Lancet Oncology (2020)

The outbreak of the COVID-19 pandemic has resulted in major disruptions to cancer care worldwide, including cancer screening programmes. These interruptions will almost certainly lead to a surge in demand for cancer services that could overwhelm health systems. However, an increased focus on the prevention and early diagnosis of cancer could increase health-system resilience and lessen reliance on resource-intensive interventions, because early stage cancers can be treated more effectively, and cost-efficiently, than advanced stage disease.
Intramyocardial Hemorrhage and the “Wave Front” of Reperfusion Injury Compromising Myocardial Salvage
Authors: Ting Liu, Andrew G. Howarth, Yinyin Chen, Anand R. Nair, Hsin-Jung Yang, Daoyuan Ren, Richard Tang, Jane Sykes, Michael S. Kovacs, Damini Dey, Piotr Slomka, John C. Wood, Robert Finney, Mengsu Zeng, Frank S. Prato, Joseph Francis, Daniel S. Berman, Prediman K. Shah, Andreas Kumar, Rohan Dharmakumar
Journal: Journal of the American College of Cardiology (2022)
Severe Acute Respiratory Syndrome—Taiwan, 2003
Journal: JAMA (2003)

On April 22, 2003, the Taiwan Department of Health (DOH) was notified of seven cases of severe acute respiratory syndrome (SARS) among health-care workers (HCWs) at a large municipal hospital in Taipei (hospital A). Subsequent cases at eight hospitals have been associated with exposures at hospital A. Previously, all reported cases had been associated with persons recently returning to Taiwan from SARS-affected regions. This report summarizes epidemiologic findings of the outbreak in Taiwan and describes the impact of health-care--associated transmission of SARS.
Microorganospheres as a novel precision oncology platform in colorectal cancer.
Authors: Carolyn Hsu, Zhaohui Wang, Sehwa Oh, Gabrielle Rupprecht, Kelly Pittman, Amber Smith, Daniel Delubac, Xiling Shen, Jingquan Jia, Shiaowen David Hsu
Journal: Journal of Clinical Oncology (2022)

149 Background: Patient-derived organoids (PDO) have been shown to have a high degree of similarity to the original patient tumors. PDO have also been used to perform high throughput drug screens and shown to correlate with patient response to therapy. Unfortunately, PDO require too much tissue, take too long to establish and are too inefficient and costly for adoption into the clinic. The ideal assay for clinical use would be one that could be performed in less than14 days from a core biopsy to minimize delay in therapy. We have now circumvented these barriers by leveraging recent technological advances in emulsion microfluidics and droplet generators to develop MicroOrganoSpheres (MOS) that can be established and used to predict drug sensitivity within 14 days of obtaining a biopsy. Methods: 18-gauge core biopsy specimens from patients with colorectal cancer liver metastasis who subsequently received an oxaliplatin based therapy were first obtained. Biopsy specimens were minced, enzymatically digested and mixed with components necessary to generate MOS. The mixture was then processed through a custom fabricated flow-focusing droplet microfluidic chip in our MOS Generator Device to generate MOS. After culturing for 8-10 days, MOS were then used to perform drug screen with oxaliplatin. Results: A total of twelve CRC biopsies from liver metastasis were obtained and processed to generate MOS with a success rate of 12/12 (100%). Furthermore, drug screens with oxaliplatin were performed on all twelve samples with an average time to drug screen of 10.1 days. We next wanted to determine if there was a correlation between MOS drug sensitivity and patient clinical outcome (ie. time on treatment). For the first eight patients, MOS was used to predict sensitivity to oxaliplatin and using a drug sensitivity cut-off of 1 uM, four patients were predicted to be sensitive to oxaliplatin and four patients were predicted to be resistant. Three of the four patients predicted to be sensitive to oxaliplatin continue to be on treatment (&gt; 6 months), whereas 3 of the four patients predicted to be resistant to oxaliplatin progressed on oxaliplatin based therapy within 8 weeks (sensitivity = 80%, specificity = 100%, positive predictive value = 100%, negative predictive value = 75%). Conclusions: MOS can be generated from core biopsies and correlates to time on treatment. Although further studies will need to be conducted, the ability to generate MOS and perform a drug screen in &lt; 14 days will allow for the development of a precision oncology platform that can be rapidly used in the clinic to guide therapy.
Chronic pulmonary reaction to nitrofurantoin
Authors: N. S. Jayasundera
Journal: JAMA (1980)

ACUTE pulmonary response to short-term therapy with nitrofurantoin was described first in 1962 and was followed in 1966 by the description of a severe, debilitating, subacute pulmonary response.<sup>1</sup>Since that time, 40 subacute and chronic pulmonary responses to long-term nitrofurantoin therapy have been recorded in the English medical literature, and biopsy specimens in some have shown the process to resemble desquamative interstitial pneumonia.<sup>1-15</sup>It is generally considered that the correct treatment is to discontinue administration of the offending agent and substitute a course of oral corticosteroids. <h3>Report of a Case</h3> A 59-year-old man was seen in September 1978 with a history of productive cough and progressive dyspnea. In 1976, a right lower lobectomy following trauma had disclosed some interstitial pulmonary fibrosis. Chest x-ray films obtained on the current admission showed bilateral basilar interstitial fibrosis and pleural thickening. A previous roentgenogram in September 1977 had been normal. On this
Ivan Petrovitch Pavlov, (1849-1936) conditioned reflexes
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TCTAP A-046 Everolimus- Versus Zotarolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions (From an IRIS-MAIN Registry Substudy)
Authors: Yu Na Kim, Seung-Jung Park, Seong-Wook Park, Cheol Whan Lee, Young-Hak Kim, Seung-Whan Lee, Duk-Woo Park, Soo-Jin Kang, Jung-Min Ahn, Pil Hyung Lee, Se Hun Kang, Cheol Hyun Lee, Min Soo Cho, Jae Seok Bae, Sung Han Yoon, Do-Yoon Kang, Mineok Chang, Jae-Hyung Roh
Journal: Journal of the American College of Cardiology (2016)
Predictors of restenosis following gamma radiation for treatment of in-stent stenoses S. Chiu Wong, Paul Teirstein, Jeffrey Moses, Prabhakor Tripuraneni, Bryan Kluck, Shirish Jani, Dean Kereiakes, Barry George, Carol I. Duffy, Martin B. Leon. The New York Presbyterian Hospital - Cornell Campus, New York, NY, Lenox Hill Heart and Vascular Institute, New York, NY
Journal: Journal of the American College of Cardiology (2001)
Coronary thermosensor basket catheler with thermographic imaging software for thermal detection of vulnerable atherosclerotic plaques Khawar Gul, Tim O'Brien, Said Siadaty, Mohammad Madjid, Reza Mohammadi, Tarun Tewatia, James T. Willerson, Ward Casscells, Morteza Naghavi. University of Texas-Houston, Houston, TX, Temperature Specialist Inc., St. Francis, MN
Journal: Journal of the American College of Cardiology (2001)